Progress in the discovery of orally bioavailable inhibitors of HIV protease
- 1 July 1995
- journal article
- Published by Springer Nature in Perspectives in Drug Discovery and Design
- Vol. 2 (3) , 427-436
- https://doi.org/10.1007/bf02172035
Abstract
No abstract availableKeywords
This publication has 42 references indexed in Scilit:
- Reduction Of The In Vitro Activity Of A77003, An Inhibitor Of Human Immunodeficiency Virus Protease, By Human Serum 1 Acid GlycoproteinThe Journal of Infectious Diseases, 1995
- Protein binding of human immunodeficiency virus protease inhibitor KNI-272 and alteration of its in vitro antiretroviral activity in the presence of high concentrations of proteinsAntimicrobial Agents and Chemotherapy, 1994
- CGP 53437, an orally bioavailable inhibitor of human immunodeficiency virus type 1 protease with potent antiviral activityAntimicrobial Agents and Chemotherapy, 1993
- HIV proteinase inhibitorsBiochemical Society Transactions, 1992
- The HIV-1 Protease as a Therapeutic Target for AIDSAIDS Research and Human Retroviruses, 1992
- Antiviral and pharmacokinetic properties of C2 symmetric inhibitors of the human immunodeficiency virus type 1 proteaseAntimicrobial Agents and Chemotherapy, 1991
- HIV protease: a novel chemotherapeutic target for AIDSJournal of Medicinal Chemistry, 1991
- Human immunodeficiency virus protease: A target for aids therapyDrug Development Research, 1990
- Active human immunodeficiency virus protease is required for viral infectivity.Proceedings of the National Academy of Sciences, 1988
- A structural model for the retroviral proteasesNature, 1987